Associated Papers
Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation.
Kanayama M et al.
The Prostate, 2026
Discovery of a Recurrent Frameshift Ashkenazi Jewish Founder Mutation (F722fs) in the PARP Inhibitor-sensitive MMS22L Gene Associated with Higher Risk of Prostate Cancer.
Isaacs WB et al.
European Urology Focus, 2025
Select a paper to view details